T cell re-directing therapies in relapsed/refractory multiple myeloma
LINKS TO ABSTRACTS:
Presentation ID p418-1
(S190) EFFICACY AND SAFETY OF THE BCMA-DIRECTED CAR-T CELL THERAPY, CILTACABTAGENE AUTOLEUCEL, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1–3 PRIOR LINES OF THERAPY: INITIAL RESULTS FROM CARTITUDE-2Presenter: Mounzer Agha, Pittsburgh, United States
The study authors conclude that a single ciltacaptagene-autoleucel (cilta-cel) infusion at the recommended phase 2 dose led to early and deep responses with manageable safety in patients with MM who had received 1–3 prior LOT. Updated efficacy and safety findings will inform the suitability of outpatient treatment in this and other cohorts of CARTITUDE-2 as well as the CARTITUDE-4 study.
Presentation ID p418-2
(S191) TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) × CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF A PHASE 1, FIRST-IN-HUMAN STUDY
Presenter: Amrita Krishnan, Duarte, United States
The study authors conclude that Talquetamab, at the RP2D of weekly 405 μg/kg SC, demonstrated a high clinical response rate and was well-tolerated in patients with relapsed/refractory MM. Based on the pharmacokinetic data, other SC dosing strategies are also being explored. According to the authors, the promising efficacy and safety profile, and the convenience of SC dosing support monotherapy development and combination approaches with this novel agent.
Presentation ID p418-3
(S192) MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) TARGETED CD3-ENGAGING BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)
Presenter: Caitlin Costello, United States
The study authors conclude that Elranatamab demonstrated a manageable safety profile and wide therapeutic index. Doses ≥215μg/kg SC achieved ORR of 75% with CR/sCR rate of 30%. According to the authors, these results demonstrate the safety and efficacy of elranatamab in this relapsed/refractory population, confirm the feasibility and potential of BCMA- directed immunotherapy for malignant plasma cell disorders, and support ongoing development of elranatamab for patients with MM.
Presentation ID p418-4
Presenter: Niels van de Donk, Amsterdam, The Netherlands
The study authors conclude that at the RP2D of weekly 1500 μg/kg SC, teclistamab was well-tolerated and demonstrated encouraging efficacy with durable, deepening responses, warranting further investigation as monotherapy and in combination with other agents.
The study authors conclude that CT103A is safe, highly productive, and long persistent in RRMM patients and can be developed as a promising therapy for RRMM. Patients who relapsed from prior non-human BCMA CAR T-cell therapy could still benefit from CT103A.